Please login to the form below

Not currently logged in
Email:
Password:

Polleo Pharma co-founders join Chronos Therapeutics

Dr Fraser Murray and Dr Timonthy Schulz-Utermoehl become pre-clinical development VPs

Chronos Dr Fraser MurrayOxford, UK-based Chronos Therapeutics has appointed Dr Fraser Murray and Dr Timothy Schulz-Utermoehl as vice presidents of pre-clinical development.

Together, they will oversee three pre-clinical research programmes recently acquired by the privately-held biotech, which target fatigue in multiple sclerosis, addictive behaviours and post-traumatic stress disorder, respectively.

Dr Murray (pictured above) brings over 20 years of drug discovery and early development experience to the role, spread across a range of therapeutic areas including dermatology, inflammation, neurodegeneration, psychiatry.

Prior to co-founding Polleo Pharma in 2014, Dr Murray served as senior director and head of discovery biology for Shire Specialty Pharmaceuticals, with a focus on central nervous system and gastrointestinal disorders.

He has also held a number of leadership roles at AstraZeneca, Calcico Therapeutics and Merck & Co.

Chronos Dr Timothy Schulz-UtermoehlMeanwhile, Dr Schulz-Utermoehl (pictured left) brings 17 years of early- and late-stage discovery research and preclinical development expertise to Chronos.

As well as co-founding Polleo Pharma alongside Dr Murray, he has worked at AstraZeneca, Merck & Co, Novo Nordisk and, most recently, Shire, where he served as a director in its exploratory projects department in the UK.

Chief executive officer of Chronos Dr Huw Jones said: “We are delighted to welcome Fraser and Timothy to Chronos at a time of significant expansion of our research portfolio.

“They bring substantial pre-clinical development expertise to our organisation and are synergistic to our recent acquisition.
“In particular, their experience as co-founders of Polleo will be invaluable as we advance our behavioural brain disease portfolio.”

4th August 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics